NASDAQ:APM Aptorum Group (APM) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free APM Stock Alerts $4.75 -0.35 (-6.86%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.72▼$5.1350-Day Range$4.33▼$10.5552-Week Range$1.35▼$17.49Volume24,407 shsAverage Volume24,101 shsMarket Capitalization$24.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Aptorum Group alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Aptorum Group Stock (NASDAQ:APM)Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Read More APM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APM Stock News HeadlinesApril 30, 2024 | businesswire.comAptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateMarch 21, 2024 | finance.yahoo.comAptorum Group Limited (APM)March 12, 2024 | cnn.comAptorum Group Limited Class AMarch 6, 2024 | finance.yahoo.comAptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessMarch 6, 2024 | investorplace.com5 Investors Betting Big on Aptorum (APM) GroupMarch 6, 2024 | investorplace.comWhy Is Aptorum (APM) Stock Up 346% Today?February 22, 2024 | investing.comAptorum Group Ltd Class A (APM)December 30, 2023 | lse.co.ukAptorum Group Cl A Share ChatDecember 26, 2023 | seekingalpha.comAptorum Group GAAP EPS of -$1.43, revenue of $0.43MDecember 22, 2023 | finance.yahoo.comAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023November 16, 2023 | finance.yahoo.comAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023November 9, 2023 | morningstar.comAptorum Group Ltd Class A APMSeptember 14, 2023 | benzinga.comAutism Summit Garners Over 30,000 Attendees: APM Announces Date of its Upcoming ConferenceAugust 8, 2023 | finance.yahoo.comAPM - Aptorum Group LimitedJune 27, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaJune 22, 2023 | finance.yahoo.comAptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaJune 9, 2023 | finance.yahoo.comAptorum Group Limited Announces Voluntary Delisting from Euronext ParisMay 26, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity DeficiencyMay 5, 2023 | finance.yahoo.comAptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity DeficiencyMay 4, 2023 | msn.comWhy Arconic Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketMay 1, 2023 | finance.yahoo.comAptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations LimitedMay 1, 2023 | finance.yahoo.comAptorum Group Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagApril 28, 2023 | finance.yahoo.comAptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business UpdateApril 25, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Announces Completion of $3 Million Convertible Note due 2023April 25, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Announces 1-for-10 Reverse Stock SplitSee More Headlines Receive APM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptorum Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/19/2024Next Earnings (Estimated)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APM CUSIPN/A CIK1734005 Webwww.aptorumgroup.com Phone442080929299FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.20 Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$430,000.00 Price / Sales57.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.60Miscellaneous Outstanding Shares5,180,000Free Float1,866,000Market Cap$24.61 million OptionableNot Optionable Beta0.85 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Chung Yuen Huen (Age 44)Founder, CEO & Non-Executive Director Comp: $923.66kMr. Martin Siu (Age 45)Head of Finance Comp: $87.34kKey CompetitorsTherapeuticsMDNASDAQ:TXMDRenovoRxNASDAQ:RNXTBullfrog AINASDAQ:BFRGLisata TherapeuticsNASDAQ:LSTAForte BiosciencesNASDAQ:FBRXView All CompetitorsInstitutional OwnershipMurchinson Ltd.Bought 14,000 shares on 5/16/2024Ownership: 0.270%View All Institutional Transactions APM Stock Analysis - Frequently Asked Questions How have APM shares performed in 2024? Aptorum Group's stock was trading at $2.45 on January 1st, 2024. Since then, APM shares have increased by 93.9% and is now trading at $4.75. View the best growth stocks for 2024 here. When is Aptorum Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 30th 2024. View our APM earnings forecast. When did Aptorum Group's stock split? Shares of Aptorum Group reverse split on Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Aptorum Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptorum Group investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Aridis Pharmaceuticals (ARDS). Who are Aptorum Group's major shareholders? Aptorum Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Murchinson Ltd. (0.27%). How do I buy shares of Aptorum Group? Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.